UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000035528
Receipt No. R000040478
Scientific Title Study on the safety of hepatic arterial infusion of cultured autologous bone marrow cells in patients with decompensated liver cirrhosis
Date of disclosure of the study information 2019/01/15
Last modified on 2019/07/17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Study on the safety of hepatic arterial infusion of cultured autologous bone marrow cells in patients with decompensated liver cirrhosis
Acronym Study on the safety of liver regeneration therapy with hepatic arterial infusion of cultured autologous bone marrow cells
Scientific Title Study on the safety of hepatic arterial infusion of cultured autologous bone marrow cells in patients with decompensated liver cirrhosis
Scientific Title:Acronym Study on the safety of liver regeneration therapy with hepatic arterial infusion of cultured autologous bone marrow cells
Region
Japan

Condition
Condition decompensated liver cirrhosis
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the safety of invasive liver regeneration therapy with hepatic artery infusion of cultured autologous bone marrow cells in patients with decompensated cirrhosis.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase I

Assessment
Primary outcomes The incidence of adverse events with hepatic arterial infusion of cultured autologous bone marrow cells
Key secondary outcomes (1) Child-Pugh score
(2) Serum albumin levels
(3) Serum fibrosis markers
(4) Liver stiffness
(5) Portal blood flow

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Other
Interventions/Control_1 Hepatic arterial infusion of cultured autologous bone marrow-derived mesenchymal stem cells
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >=
Gender Male and Female
Key inclusion criteria (1) Patients with decompensated liver cirrhosis with a Child-Pugh score of 7 or higher (Child-Pugh B) at two points separated by at least 90 days, in whom further improvement is not expected with current medical treatment.
(2) Patients aged 20 to 75 years.
(3) Patients from whom written consent for participation in this clinical study was obtained.
Key exclusion criteria (1) Patients with a current history of malignant neoplasm.
(2) Patients with gastroesophageal varices at risk of rupture.

(5) Patients with a hemoglobin <8 g/dL, a platelet count <50,000/uL, or a prothrombin time <40%.
(6) Patients with renal insufficiency and a serum creatinine greater than or equal to 2 mg/dL.
(7) Patients with a performance status of 3 or 4.
(8) Patients who refuse to consent to allogeneic blood transfusion.
(10) Women who are pregnant.
(12) Patients with a current or previous severe allergic reaction to anesthesia.
(13) Patients with a current or previous severe allergic reaction to a contrast agent.
(14) Patients with a current or previous severe allergic reaction to beef, cow milk.
(15) Patients who had an experience with other cell therapy or other clinical study of cell therapy.
(17) Any patient deemed unsuitable for study inclusion by their attending physician.
Target sample size 5

Research contact person
Name of lead principal investigator
1st name Taro
Middle name
Last name Takami
Organization Yamaguchi University Hospital
Division name Department of Gastroenterology and Hepatology
Zip code 755-8505
Address 1-1-1 Minami-kogushi, Ube, Yamaguchi, Japan
TEL +81836222241
Email t-takami@yamaguchi-u.ac.jp

Public contact
Name of contact person
1st name Taro
Middle name
Last name Takami
Organization Yamaguchi University
Division name Department of Gastroenterology and Hepatology
Zip code 755-8505
Address 1-1-1 Minami-kogushi, Ube, Yamaguchi, Japan
TEL +81836222241
Homepage URL
Email t-takami@yamaguchi-u.ac.jp

Sponsor
Institute Yamaguchi University Hospital
Institute
Department

Funding Source
Organization Yamaguchi Pref and self funding
Organization
Division
Category of Funding Organization Local Government
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Yamaguchi University Hospital Certified Committee for Regenerative Medicine
Address 1-1-1 Minami-kogushi, Ube, Yamaguchi, Japan
Tel 0836-22-2428
Email ysaisei@yamaguchi-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 01 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2018 Year 01 Month 15 Day
Date of IRB
2018 Year 02 Month 19 Day
Anticipated trial start date
2018 Year 02 Month 19 Day
Last follow-up date
2021 Year 08 Month 19 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 01 Month 12 Day
Last modified on
2019 Year 07 Month 17 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040478

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.